

CLAIMS

What is claimed is:

- Sub B
B1
1. A nucleic acid delivery vehicle having at least a tissue tropism for mesenchymal stem cells.
 2. The nucleic acid delivery vehicle of claim 1, further having at least partially reduced tissue tropism for liver cells.
 - Sub B
B1
 3. The nucleic acid delivery vehicle of claim 1 or claim 2, wherein said tissue tropism is provided by at least a part of a virus capsid or a functional derivative and/or analogue thereof.
 - Sub B
B1
 4. The nucleic acid delivery vehicle of claim 3, wherein said virus capsid comprises proteins, or functional parts, derivatives and/or analogues thereof, from at least two different viruses.
 5. The nucleic acid delivery vehicle of claim 4, wherein at least one of said at least two different viruses is an adenovirus.
 - Sub B
B2
 6. The nucleic acid delivery vehicle of claim 4 or claim 5, wherein at least one of said at least two different viruses is an adenovirus of subgroup B.
 7. The nucleic acid delivery vehicle of claim 4, claim 5, or claim 6, wherein at least one of said proteins comprises a tissue tropism determining part of a fiber protein derived from a subgroup B adenovirus a functional derivative and/or analogue thereof.
 8. The nucleic acid delivery vehicle of claim 6 or claim 7, wherein said subgroup B adenovirus is adenovirus 16.

Sub A2
9. The nucleic acid delivery vehicle of claim 6, claim 7, or claim 8, further comprising at least one protein derived from an adenovirus not belonging to subgroup B, or a functional part, derivative and/or analogue thereof.

Sub B
10. The nucleic acid delivery vehicle of claim 9, wherein said at least one protein or a functional part, derivative and/or analogue thereof not derived from an adenovirus of subgroup B is derived from an adenovirus of subgroup C.

Sub A3
11. The nucleic acid delivery vehicle of any one of claims 1 through 10, further comprising adenoviral nucleic acid.

12. The nucleic acid delivery vehicle of any one of claims 1 through 11, comprising adenoviral nucleic acid from at least two different adenoviruses.

13. The nucleic acid delivery vehicle of claim 11 or claim 12, wherein said adenoviral nucleic acid at least encodes a fiber protein comprising at least a tissue tropism determining part of a subgroup B adenovirus fiber protein or a functional derivative and/or analogue thereof.

14. The nucleic acid delivery vehicle of claim 11, claim 12 or claim 13, wherein said adenoviral nucleic acid is a modified nucleic acid such that the capacity of said adenoviral nucleic acid to replicate in a target cell has been reduced or disabled.

15. The nucleic acid delivery vehicle of any one of claims 11 through 14, wherein said adenoviral nucleic acid is a modified nucleic acid such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said adenoviral nucleic acid has been diminished.

16. The nucleic acid delivery vehicle of any one of claims 1 through 15, further comprising a minimal adenovirus vector or an Ad/AAV chimeric vector.

Sub A3
17. The nucleic acid delivery vehicle of any one of claims 1 through 16, further comprising at least one nucleic acid of interest.

18. The nucleic acid delivery vehicle of any one of claims 1 through 17, wherein said nucleic acid delivery vehicle is a subgroup B adenovirus capsid comprising at least one nucleic acid of interest.

Sub B
19. The nucleic acid delivery vehicle of claim 18, wherein said at least one nucleic acid of interest further comprises at least one subgroup B adenovirus nucleic acid.

20. The nucleic acid delivery vehicle of claim 19, wherein said at least one subgroup B adenovirus nucleic acid has been deprived of the capacity to express E1-region encoded proteins.

Sub A4
21. The nucleic acid delivery vehicle of claim 18, claim 19, or claim 20, wherein said subgroup B adenovirus capsid is derived from adenovirus 16.

22. A process for producing the nucleic acid delivery vehicle of any one of claims 1 through 21, said method comprising:

providing a cell with means for the assembly of said nucleic acid delivery vehicle wherein said means includes a means for the production of an adenovirus fiber protein, wherein said adenovirus fiber protein comprises at least a tissue tropism determining part of a subgroup B adenovirus or a functional derivative and/or analogue thereof.

23. A cell for the production of the nucleic acid delivery vehicle of any one of claims 1 through 21, said cell comprising:

means for the assembly of said nucleic acid delivery vehicle wherein said means includes a means for the production of an adenovirus fiber protein, wherein said adenovirus fiber

Sub A4
protein comprises at least a tissue tropism determining part of a subgroup B adenovirus fiber protein.

24. A pharmaceutical preparation comprising the nucleic acid delivery vehicle of any one of claims 1 to 21.

Sub B1
25. A method for the treatment of a disease that is treatable by transfer of a nucleic acid encoding a therapeutic proteinaceous molecule or RNA to mesenchymal stem cells comprising administering the pharmaceutical preparation of claim 24.

Sub A3
26. A method for the delivery of nucleic acid to mesenchymal stem cells comprising administering the nucleic acid delivery vehicle of any one of claims 1 to 22.

27. A method for the generation of a nucleic acid library comprising analyzing the nucleic acid delivery vehicle of any one of claims 1 to 21.

Sub B1
28. A method for the delivery of nucleic acid to a mesenchymal stem cell comprising administering the nucleic acid delivery vehicle of claim 1, wherein said nucleic acid delivery vehicle comprises a fiber protein of adenovirus 16 or a functional part, derivative and/or analogue thereof.

Sub A6
29. A pharmaceutical preparation for the treatment of rheumatoid arthritis comprising the nucleic acid delivery vehicle of any one of claims 1 to 21.

Sub B1
30. The pharmaceutical preparation of claim 29, wherein said nucleic acid delivery vehicle comprises a gene encoding IL-10 or a functional equivalent thereof.

Sub A7
31. A method for tissue engineering comprising administering the nucleic acid delivery vehicle of any one of claims 1 to 22.

32. A pharmaceutical preparation for providing bone regeneration comprising the nucleic acid delivery vehicle of any one of claims 1 to 22.

Sub A
33. A pharmaceutical preparation for providing bone regeneration comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of any one of claims 1 to 22.

34. The pharmaceutical preparation of claim 32 or claim 33 wherein said nucleic acid delivery vehicle is provided with a gene encoding bone morphogenesis protein-2 and/or LIM mineralization protein-1 or a functional equivalent of either.

35. A pharmaceutical preparation for the treatment of multiple sclerosis comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of any one of claims 1-22.

36. A pharmaceutical preparation for promoting angiogenesis comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of any one of claims 1-22.

37. A mesenchymal stem cell comprising a nucleic acid delivered to said mesenchymal stem cell through the nucleic acid delivery vehicle of any one of claims 1-21.

Sub B
38. The nucleic acid delivery vehicle of claim 7, wherein said subgroup B adenovirus is selected from the group consisting of serotypes 11, 16, 35, and 51.

39. The nucleic acid delivery vehicle of claim 10, wherein said adenovirus of subgroup C comprises serotype 5.

40. The nucleic acid delivery vehicle of claim 13, wherein said subgroup B adenovirus fiber protein is derived from the group consisting of serotypes 11, 16, 35, and 51.
41. The nucleic acid delivery vehicle of claim 13, wherein said subgroup B adenovirus fiber protein is derived from serotype 16.
42. The nucleic acid delivery vehicle of claim 11, wherein said nucleic acid is a modified nucleic acid such that the capacity of said nucleic acid to replicate in a target cell has been reduced or disabled through a deletion of at least part of the E1-region.
43. The nucleic acid delivery vehicle of claim 11, wherein said nucleic acid is a modified nucleic acid such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said nucleic acid has been reduced or disabled through a deletion of E2A and/or at least a part of the E4-region.
44. The method according to claim 22, wherein said subgroup B adenovirus is selected from the group consisting of serotypes 11, 16, 35, and 51.
45. The cell of claim 23, wherein said subgroup B adenovirus fiber protein is derived from the group consisting of serotypes 11, 16, 35, and 51.
46. The cell of claim 23, wherein said cell is or is derived from a PER.C6 cell.
47. A method for the generation of a nucleic acid library comprising analyzing the cell of claim 23.